首页 > 最新文献

Intractable & rare diseases research最新文献

英文 中文
KCNB1 frameshift variant caused inherited intellectual disability, developmental delay, and seizure. KCNB1移码变体可导致遗传性智力残疾、发育迟缓和癫痫发作。
IF 1.3 Q2 Medicine Pub Date : 2022-11-01 DOI: 10.5582/irdr.2022.01096
Eyyup Uctepe, Fatma Nisa Esen, Sait Tümer, Hanifenur Mancılar, Ahmet Yeşilyurt

Potassium voltage-gated channel subfamily B member 1 (KCNB1) encodes Kv2.1 potassium channel. KCNB1 mutations are known to cause global developmental delay, behavioral disorders, and various epilepsies. Most variants occur de novo and are rarely inherited. Here, we report a 14-year-old male patient who was admitted to our clinic with seizures, developmental delay history, and intellectual disability. Brain magnetic resonance image (MRI) was normal and electroencephalogram (EEG) showed spike and sharp-wave complexes emerging in the left hemisphere parietooccipital areas, which were paroxysmally generalized. We performed whole exome sequence analysis (WES) and identified a heterozygous frameshift mutation c.522delA in exon 1 of KCNB1 (NM_004975.4) predicting a premature stop codon p.Lys174Asnfs*20 in the proband. Sanger sequencing confirmed the heterozygous c.522delA mutation in the proband and his mother who also had epilepsy and learning difficulties. His 45 year old mother had used antiepileptic drugs for 9 years after a seizure episode at 12 years old. Also, his mother's uncle's son is nonverbal and has developmental delay and epilepsy. Our study shows that frameshift mutation cytoplasmic domain of KCNB1 gene can cause intrafamilial phenotypic variability and relatively mild clinical findings in these patients.

钾电压门控通道亚家族B成员1 (KCNB1)编码Kv2.1钾通道。已知KCNB1突变可导致整体发育迟缓、行为障碍和各种癫痫。大多数变异都是从头开始的,很少遗传。在这里,我们报告一位14岁的男性患者,他因癫痫发作、发育迟缓史和智力残疾而入院。脑磁共振(MRI)检查正常,脑电图(EEG)显示左半球顶枕区出现突波和锐波复合物,呈阵发性广泛性。我们进行了全外显子序列分析(WES),在KCNB1 (NM_004975.4)的外显子1中发现了一个杂合移码突变c.522delA,预测了先证子中过早停止密码子p.Lys174Asnfs*20。桑格测序证实了先证和他患有癫痫和学习困难的母亲的杂合c.522delA突变。他45岁的母亲在12岁时癫痫发作后服用了9年的抗癫痫药物。而且,他母亲的叔叔的儿子不会说话,有发育迟缓和癫痫。我们的研究表明,KCNB1基因胞质结构域移码突变可导致这些患者的家族内表型变异和相对轻微的临床表现。
{"title":"KCNB1 frameshift variant caused inherited intellectual disability, developmental delay, and seizure.","authors":"Eyyup Uctepe,&nbsp;Fatma Nisa Esen,&nbsp;Sait Tümer,&nbsp;Hanifenur Mancılar,&nbsp;Ahmet Yeşilyurt","doi":"10.5582/irdr.2022.01096","DOIUrl":"https://doi.org/10.5582/irdr.2022.01096","url":null,"abstract":"<p><p>Potassium voltage-gated channel subfamily B member 1 (<i>KCNB1</i>) encodes Kv2.1 potassium channel. KCNB1 mutations are known to cause global developmental delay, behavioral disorders, and various epilepsies. Most variants occur de novo and are rarely inherited. Here, we report a 14-year-old male patient who was admitted to our clinic with seizures, developmental delay history, and intellectual disability. Brain magnetic resonance image (MRI) was normal and electroencephalogram (EEG) showed spike and sharp-wave complexes emerging in the left hemisphere parietooccipital areas, which were paroxysmally generalized. We performed whole exome sequence analysis (WES) and identified a heterozygous frameshift mutation c.522delA in exon 1 of <i>KCNB1</i> (NM_004975.4) predicting a premature stop codon p.Lys174Asnfs*20 in the proband. Sanger sequencing confirmed the heterozygous c.522delA mutation in the proband and his mother who also had epilepsy and learning difficulties. His 45 year old mother had used antiepileptic drugs for 9 years after a seizure episode at 12 years old. Also, his mother's uncle's son is nonverbal and has developmental delay and epilepsy. Our study shows that frameshift mutation cytoplasmic domain of <i>KCNB1</i> gene can cause intrafamilial phenotypic variability and relatively mild clinical findings in these patients.</p>","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709620/pdf/irdr-11-219.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40457021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Assessment of health-related quality of life in patients with spina muscular atrophy in China. 中国脊髓性肌萎缩症患者健康相关生活质量评估
IF 1.3 Q2 Medicine Pub Date : 2022-11-01 DOI: 10.5582/irdr.2022.01094
Chengaxin Duan, Dandan Ai, Qian Xu, Binyan Sui, Kun Zhao

Spinal muscular atrophy (SMA) is a rare disease that has attracted considerable interest in China due to its severity and hefty treatment costs. Few studies have been conducted on Chinese patients. The objective of this study was to assess the quality of life of SMA patients in China and to investigate the real impact of new treatments. We used the Pediatric Quality of Life Inventory (PedsQL) to analyze the Health-related quality of life (HRQoL) of patients with SMA in China. Information on demographics, disease-specific characteristics, and treatment were collected using a child-reported or proxy-reported questionnaire. The mean scores of HRQoL for the Nusinersen treatment group and conventional treatment groups are 55.6 and 48.4, respectively. Patients with SMA type I have the lowest scores, while those with type III have the highest scores. A higher proportion of the medication group showed improvement in the condition in the past six months (56.9% vs. 17.1%). Our results show that the clinical type, motor function and treatment strategy have a significant influence on HRQoL. The findings imply that Nusinersen benefits patients by slowing the progression of the disease and increasing their quality of life in the real world.

脊髓性肌萎缩症(SMA)是一种罕见的疾病,由于其严重程度和高昂的治疗费用,在中国引起了相当大的兴趣。很少有针对中国患者的研究。本研究的目的是评估中国SMA患者的生活质量,并探讨新疗法的实际影响。我们使用儿科生活质量量表(PedsQL)分析中国SMA患者的健康相关生活质量(HRQoL)。使用儿童报告或代理报告问卷收集人口统计、疾病特异性特征和治疗方面的信息。Nusinersen治疗组和常规治疗组HRQoL平均评分分别为55.6分和48.4分。SMA I型患者得分最低,而III型患者得分最高。服药组在过去6个月内病情改善的比例较高(56.9% vs. 17.1%)。结果表明,临床类型、运动功能和治疗策略对HRQoL有显著影响。研究结果表明,Nusinersen通过减缓疾病的进展和提高他们在现实世界中的生活质量而使患者受益。
{"title":"Assessment of health-related quality of life in patients with spina muscular atrophy in China.","authors":"Chengaxin Duan,&nbsp;Dandan Ai,&nbsp;Qian Xu,&nbsp;Binyan Sui,&nbsp;Kun Zhao","doi":"10.5582/irdr.2022.01094","DOIUrl":"https://doi.org/10.5582/irdr.2022.01094","url":null,"abstract":"<p><p>Spinal muscular atrophy (SMA) is a rare disease that has attracted considerable interest in China due to its severity and hefty treatment costs. Few studies have been conducted on Chinese patients. The objective of this study was to assess the quality of life of SMA patients in China and to investigate the real impact of new treatments. We used the Pediatric Quality of Life Inventory (PedsQL) to analyze the Health-related quality of life (HRQoL) of patients with SMA in China. Information on demographics, disease-specific characteristics, and treatment were collected using a child-reported or proxy-reported questionnaire. The mean scores of HRQoL for the Nusinersen treatment group and conventional treatment groups are 55.6 and 48.4, respectively. Patients with SMA type I have the lowest scores, while those with type III have the highest scores. A higher proportion of the medication group showed improvement in the condition in the past six months (56.9% <i>vs.</i> 17.1%). Our results show that the clinical type, motor function and treatment strategy have a significant influence on HRQoL. The findings imply that Nusinersen benefits patients by slowing the progression of the disease and increasing their quality of life in the real world.</p>","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709625/pdf/irdr-11-189.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40556984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monoclonal gammopathy of undetermined significance (MGUS) characterized by refractory lower gastrointestinal postoperative bleeding with coagulopathy. 以难治性下消化道术后出血伴凝血功能障碍为特征的未确定意义单克隆γ病(MGUS)。
IF 1.3 Q2 Medicine Pub Date : 2022-11-01 DOI: 10.5582/irdr.2022.01120
Shuxia Zhang, Zhifen Chen, Meijuan Huang, Rong Zhan, Long Wu, Qian Zhang, Yu Lin, Weizhong Jiang, Pan Chi, Feng'e Yang

Bleeding is a common complication after lower gastrointestinal surgery, and cases due to coagulation dysfunction are rare. The current authors encountered a 54-year-old Chinese man with refractory bleeding after endoscopic rectal polypectomy, and multiple endoscopic and surgical interventions failed to control that bleeding. An APTT mixing test could not be corrected and there was no evidence of autoimmune-related disease, so the presence of nonspecific antibodies was considered. After empiric therapy with a cyclophosphamide and glucocorticoid, APTT was corrected and gastrointestinal bleeding stopped. Based on laboratory results and therapeutic results, the patient was ultimately diagnosed with prolonged APTT induced by monoclonal gammopathy of undetermined significance (MGUS). MGUS and coagulopathy characterized by a prolonged APTT has rarely been reported. Here, studies noting elevated monoclonal immunoglobulins and coagulopathy have been reviewed. If a prolonged APTT of undetermined significance cannot be corrected with an APTT mixing test and if autoimmune-related factors are excluded, then plasma cell-related diseases such as MGUS need to be considered.

出血是下消化道手术后常见的并发症,但因凝血功能障碍引起的出血病例并不多见。本文作者遇到一位54岁的中国男性,经内镜直肠息肉切除术后出血难治性,多次内镜和手术干预均未能控制出血。APTT混合试验不能纠正,也没有自身免疫相关疾病的证据,因此考虑存在非特异性抗体。经经验性环磷酰胺和糖皮质激素治疗后,APTT得到纠正,胃肠道出血停止。根据实验室结果和治疗结果,患者最终被诊断为由未确定意义的单克隆γ病(MGUS)诱导的延长APTT。以APTT延长为特征的MGUS和凝血功能障碍很少有报道。本文回顾了单克隆免疫球蛋白升高和凝血功能障碍的研究。如果延长的APTT不确定的意义,不能纠正与APTT混合试验,如果自身免疫相关因素被排除,则需要考虑浆细胞相关疾病,如MGUS。
{"title":"Monoclonal gammopathy of undetermined significance (MGUS) characterized by refractory lower gastrointestinal postoperative bleeding with coagulopathy.","authors":"Shuxia Zhang,&nbsp;Zhifen Chen,&nbsp;Meijuan Huang,&nbsp;Rong Zhan,&nbsp;Long Wu,&nbsp;Qian Zhang,&nbsp;Yu Lin,&nbsp;Weizhong Jiang,&nbsp;Pan Chi,&nbsp;Feng'e Yang","doi":"10.5582/irdr.2022.01120","DOIUrl":"https://doi.org/10.5582/irdr.2022.01120","url":null,"abstract":"<p><p>Bleeding is a common complication after lower gastrointestinal surgery, and cases due to coagulation dysfunction are rare. The current authors encountered a 54-year-old Chinese man with refractory bleeding after endoscopic rectal polypectomy, and multiple endoscopic and surgical interventions failed to control that bleeding. An APTT mixing test could not be corrected and there was no evidence of autoimmune-related disease, so the presence of nonspecific antibodies was considered. After empiric therapy with a cyclophosphamide and glucocorticoid, APTT was corrected and gastrointestinal bleeding stopped. Based on laboratory results and therapeutic results, the patient was ultimately diagnosed with prolonged APTT induced by monoclonal gammopathy of undetermined significance (MGUS). MGUS and coagulopathy characterized by a prolonged APTT has rarely been reported. Here, studies noting elevated monoclonal immunoglobulins and coagulopathy have been reviewed. If a prolonged APTT of undetermined significance cannot be corrected with an APTT mixing test and if autoimmune-related factors are excluded, then plasma cell-related diseases such as MGUS need to be considered.</p>","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709621/pdf/irdr-11-206.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40458353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of current guidelines and consensus on the management of patients with cholangiocarcinoma: 2022 update. 胆管癌患者管理的现行指南和共识的比较:2022年更新。
IF 1.3 Q2 Medicine Pub Date : 2022-11-01 DOI: 10.5582/irdr.2022.01109
Xinyi Zhang, Yulong Cai, Xianze Xiong, Ao Liu, Rongxin Zhou, Zhen You, Fuyu Li, Nansheng Cheng

As a consequence of breakthroughs in the area of guidelines research, the therapy for cholangiocarcinoma has significantly improved the efficacy rate of diagnosis and survival outcomes. We compared the most recently updated clinical practice guidelines and consensus to provide recommendations based on the diagnostic and therapeutic equipment available in various countries. Following a systematic review, we discovered that these guidelines and consensus had both similarities and differences in terms of what organizations or groups drafted the guidelines and the approach, applicability, content and recent updates of the guidelines as well as in terms of diagnostic and treatment algorithms. The disparities could be attributable to a variety of etiological factors, high risk patients, health resources, medical technology, treatment options, and income levels. Additionally, while complete adoption of guidelines may benefit physicians, patients, and authorities, there remains a disconnect between expected goals and implementation.

由于指南研究领域的突破,胆管癌的治疗显著提高了诊断率和生存结局。我们比较了最新更新的临床实践指南和共识,根据各国现有的诊断和治疗设备提供建议。经过系统回顾,我们发现这些指南和共识在哪些组织或团体起草指南和方法、适用性、内容和指南的最新更新以及诊断和治疗算法方面既有相似之处,也有差异。这种差异可归因于多种病因、高危患者、卫生资源、医疗技术、治疗方案和收入水平。此外,虽然指南的完全采用可能使医生、患者和当局受益,但预期目标和实施之间仍然存在脱节。
{"title":"Comparison of current guidelines and consensus on the management of patients with cholangiocarcinoma: 2022 update.","authors":"Xinyi Zhang,&nbsp;Yulong Cai,&nbsp;Xianze Xiong,&nbsp;Ao Liu,&nbsp;Rongxin Zhou,&nbsp;Zhen You,&nbsp;Fuyu Li,&nbsp;Nansheng Cheng","doi":"10.5582/irdr.2022.01109","DOIUrl":"https://doi.org/10.5582/irdr.2022.01109","url":null,"abstract":"<p><p>As a consequence of breakthroughs in the area of guidelines research, the therapy for cholangiocarcinoma has significantly improved the efficacy rate of diagnosis and survival outcomes. We compared the most recently updated clinical practice guidelines and consensus to provide recommendations based on the diagnostic and therapeutic equipment available in various countries. Following a systematic review, we discovered that these guidelines and consensus had both similarities and differences in terms of what organizations or groups drafted the guidelines and the approach, applicability, content and recent updates of the guidelines as well as in terms of diagnostic and treatment algorithms. The disparities could be attributable to a variety of etiological factors, high risk patients, health resources, medical technology, treatment options, and income levels. Additionally, while complete adoption of guidelines may benefit physicians, patients, and authorities, there remains a disconnect between expected goals and implementation.</p>","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709616/pdf/irdr-11-161.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40557483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
The aberrant behavior profile in Indonesian individuals with fragile X syndrome with limited genetic services. 遗传服务有限的印度尼西亚脆性X综合征个体的异常行为特征。
IF 1.3 Q2 Medicine Pub Date : 2022-11-01 DOI: 10.5582/irdr.2022.01075
Tri Indah Winarni, Tanjung Ayu Sumekar, Widodo Sarjana, Hardian Hardian, Randi J Hagerman, Sultana Mh Faradz

Fragile X syndrome (FXS) is caused by the full mutation in the fragile x messenger ribonucleoprotein 1 (FMR1) gene leading to the absence of the fragile X protein (FXP). Previous studies show that individuals with FXS exhibit changing behavior over time; therefore, this study aimed to elucidate the aberrant behavior profile of FXS individuals. The Aberrant Behavior Checklist-Community (ABC-C) was used to measure the aberrant behavior profile of individuals with FXS, which was rated by the parent/caregiver combined with clinical impression. A total of 58 items were used to assess aberrant behaviors across five subscales. Forty-nine individuals with FXS were included (32 males, 17 females) with a mean age of 32.9 ± 14.62 years in males and 33.4 ± 13.98 years in females. The average score of irritability and hyperactivity was significantly higher in male FXS individuals (5.37 ± 6.231 and 10.28 ± 8.524) than in female individuals (3.24 ± 7.093 and 3.76 ± 3.327) with p = 0.046 and p = 0.001, respectively. Overall irritability in FXS individuals significantly decreased over time (ß = -0.141; p = 0.032). A modest worsening in lethargy/social withdrawal in males across age and a gentle improvement in hyperactivity/noncompliance in male of FXS individuals were observed. FXS males had higher hyperactivity problems than FXS female individuals across age.

脆性X综合征(Fragile X syndrome, FXS)是由脆性X信使核糖核蛋白1 (FMR1)基因完全突变导致脆性X蛋白(脆性X蛋白)缺失引起的。先前的研究表明,患有FXS的个体会随着时间的推移表现出不断变化的行为;因此,本研究旨在阐明FXS个体的异常行为特征。采用异常行为量表-社区量表(ABC-C)测量FXS个体的异常行为特征,由家长/照顾者结合临床印象对其进行评分。共有58个项目被用来评估五个子量表中的异常行为。FXS患者49例(男32例,女17例),平均年龄(男32.9±14.62岁,女33.4±13.98岁)。FXS男性个体的易怒和多动平均得分(5.37±6.231和10.28±8.524)显著高于女性个体(3.24±7.093和3.76±3.327),p = 0.046和p = 0.001。FXS个体的总体易怒程度随时间显著降低(ß = -0.141;P = 0.032)。观察到FXS个体的男性在不同年龄的嗜睡/社交退缩方面有轻微的恶化,而在多动/不服从方面有轻微的改善。不同年龄的FXS男性比FXS女性有更高的多动问题。
{"title":"The aberrant behavior profile in Indonesian individuals with fragile X syndrome with limited genetic services.","authors":"Tri Indah Winarni,&nbsp;Tanjung Ayu Sumekar,&nbsp;Widodo Sarjana,&nbsp;Hardian Hardian,&nbsp;Randi J Hagerman,&nbsp;Sultana Mh Faradz","doi":"10.5582/irdr.2022.01075","DOIUrl":"https://doi.org/10.5582/irdr.2022.01075","url":null,"abstract":"<p><p>Fragile X syndrome (FXS) is caused by the full mutation in the fragile x messenger ribonucleoprotein 1 (<i>FMR1</i>) gene leading to the absence of the fragile X protein (FXP). Previous studies show that individuals with FXS exhibit changing behavior over time; therefore, this study aimed to elucidate the aberrant behavior profile of FXS individuals. The Aberrant Behavior Checklist-Community (ABC-C) was used to measure the aberrant behavior profile of individuals with FXS, which was rated by the parent/caregiver combined with clinical impression. A total of 58 items were used to assess aberrant behaviors across five subscales. Forty-nine individuals with FXS were included (32 males, 17 females) with a mean age of 32.9 ± 14.62 years in males and 33.4 ± 13.98 years in females. The average score of irritability and hyperactivity was significantly higher in male FXS individuals (5.37 ± 6.231 and 10.28 ± 8.524) than in female individuals (3.24 ± 7.093 and 3.76 ± 3.327) with <i>p</i> = 0.046 and <i>p</i> = 0.001, respectively. Overall irritability in FXS individuals significantly decreased over time (<i>ß</i> = -0.141; <i>p</i> = 0.032). A modest worsening in lethargy/social withdrawal in males across age and a gentle improvement in hyperactivity/noncompliance in male of FXS individuals were observed. FXS males had higher hyperactivity problems than FXS female individuals across age.</p>","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709619/pdf/irdr-11-215.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40569982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated information regarding management of hepatic epithelioid hemangioendothelioma. 关于肝上皮样血管内皮瘤治疗的最新信息。
IF 1.3 Q2 Medicine Pub Date : 2022-11-01 DOI: 10.5582/irdr.2022.01113
Kaijian Chu, Zhizheng Li, Wei Tang, Xiaoqing Jiang

Hepatic epithelioid hemangioendothelioma (HEHE) is a rare hepatic vascular tumor with a borderline biological behavior between hemangioma and hemangiosarcoma. It tends to be multiple or diffuse subcapsular lesions across the liver but has no characteristic clinical manifestations or imaging findings. On computed tomography and magnetic resonance imaging, these lesions usually have a hypodense appearance with heterogeneous enhancement and a "halo sign" or "lollipop sign" may be evident in some cases. HEHE is diagnosed mainly based on a pathological examination along with differential immunohistochemical markers such as CAMTA1, CD31, CD34, CD10, vimentin, and factor VIII antigen. Currently, there are no standardized treatment guidelines for HEHE, and surgery (curative resection and liver transplantation) remains the mainstay of treatment. Studies have indicated that extra-hepatic metastasis might not be a contraindication for resection or transplantation. Systemic chemotherapeutic agents including doxorubicin, vincristine, interferon-a, 5-fluorouracil, and thalidomide, as well as VEGF-related agents are being investigated, but no agents have been approved for the treatment of HEHE.

肝上皮样血管内皮瘤(HEHE)是一种罕见的肝脏血管肿瘤,其生物学行为介于血管瘤和血管肉瘤之间。它往往是横跨肝脏的多发或弥漫性囊下病变,但没有特征性的临床表现或影像学发现。在计算机断层扫描和磁共振成像上,这些病变通常表现为低密度且不均匀强化,在某些情况下可能明显出现“光环征”或“棒棒糖征”。HEHE的诊断主要基于病理检查以及不同的免疫组织化学标志物,如CAMTA1、CD31、CD34、CD10、vimentin和factor VIII抗原。目前,HEHE没有标准化的治疗指南,手术(治愈性切除和肝移植)仍然是治疗的主要方式。研究表明肝外转移可能不是切除或移植的禁忌症。包括阿霉素、长春新碱、干扰素-a、5-氟尿嘧啶和沙利度胺在内的全身化疗药物以及vegf相关药物正在研究中,但尚未有药物被批准用于治疗HEHE。
{"title":"Updated information regarding management of hepatic epithelioid hemangioendothelioma.","authors":"Kaijian Chu,&nbsp;Zhizheng Li,&nbsp;Wei Tang,&nbsp;Xiaoqing Jiang","doi":"10.5582/irdr.2022.01113","DOIUrl":"https://doi.org/10.5582/irdr.2022.01113","url":null,"abstract":"<p><p>Hepatic epithelioid hemangioendothelioma (HEHE) is a rare hepatic vascular tumor with a borderline biological behavior between hemangioma and hemangiosarcoma. It tends to be multiple or diffuse subcapsular lesions across the liver but has no characteristic clinical manifestations or imaging findings. On computed tomography and magnetic resonance imaging, these lesions usually have a hypodense appearance with heterogeneous enhancement and a \"halo sign\" or \"lollipop sign\" may be evident in some cases. HEHE is diagnosed mainly based on a pathological examination along with differential immunohistochemical markers such as CAMTA1, CD31, CD34, CD10, vimentin, and factor VIII antigen. Currently, there are no standardized treatment guidelines for HEHE, and surgery (curative resection and liver transplantation) remains the mainstay of treatment. Studies have indicated that extra-hepatic metastasis might not be a contraindication for resection or transplantation. Systemic chemotherapeutic agents including doxorubicin, vincristine, interferon-a, 5-fluorouracil, and thalidomide, as well as VEGF-related agents are being investigated, but no agents have been approved for the treatment of HEHE.</p>","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709622/pdf/irdr-11-211.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10276235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Do patients with Hirayama disease require surgical treatment? A review of the literature. 平山病患者需要手术治疗吗?文献综述。
IF 1.3 Q2 Medicine Pub Date : 2022-11-01 DOI: 10.5582/irdr.2022.01105
Yuan Gao, Chi Sun, Xiaosheng Ma, Feizhou Lu, Jianyuan Jiang, Hongli Wang

The main clinic characteristic of Hirayama disease (HD) is atrophy of the distal muscles in the upper limbs. Recently, an increasing number of HD cases have been reported. Many HD patients have persistently progressive symptoms and conservative treatments failed. This article aims to review the current status of the field and summarizes the main surgical treatment options for patients with HD. A comprehensive search of the PubMed and the Web of Science databases was conducted from their inception to September 15th, 2022. Search terms included "juvenile muscular atrophy of upper extremity", "Hirayama disease" and "surgery". A total of 169 relevant publications were identified and 29 articles were finally reviewed. Current surgical treatments for HD are either anterior cervical surgery or posterior cervical surgery. The two approaches can effectively stop the disease. However, no studies have compared the advantages and limitations of the two surgical methods. The previous view that HD can be improved with conservative treatment has been challenged. In many studies, surgical treatment has been shown to improve the hand function in patients with HD. However, there is still controversy about the methods of anterior and posterior cervical surgery. Future research could focus on exploring the advantages and limitations of different surgeries.

平山病(HD)的主要临床特征是上肢远端肌肉萎缩。最近,有越来越多的HD病例被报道。许多HD患者有持续的进行性症状,保守治疗失败。本文旨在回顾该领域的现状,并总结HD患者的主要手术治疗方案。对PubMed和Web of Science数据库进行了全面的搜索,从它们成立到2022年9月15日。搜索词包括“青少年上肢肌肉萎缩症”、“平山病”和“手术”。共确定了169份相关出版物,并最终审查了29篇文章。目前治疗HD的手术方法是颈椎前路手术或颈椎后路手术。这两种方法可以有效地阻止这种疾病。然而,没有研究比较这两种手术方法的优点和局限性。先前认为HD可以通过保守治疗得到改善的观点受到了挑战。在许多研究中,手术治疗已被证明可以改善HD患者的手部功能。然而,关于颈椎前后路手术的方法仍存在争议。未来的研究可以重点探讨不同手术的优缺点。
{"title":"Do patients with Hirayama disease require surgical treatment? A review of the literature.","authors":"Yuan Gao,&nbsp;Chi Sun,&nbsp;Xiaosheng Ma,&nbsp;Feizhou Lu,&nbsp;Jianyuan Jiang,&nbsp;Hongli Wang","doi":"10.5582/irdr.2022.01105","DOIUrl":"https://doi.org/10.5582/irdr.2022.01105","url":null,"abstract":"<p><p>The main clinic characteristic of Hirayama disease (HD) is atrophy of the distal muscles in the upper limbs. Recently, an increasing number of HD cases have been reported. Many HD patients have persistently progressive symptoms and conservative treatments failed. This article aims to review the current status of the field and summarizes the main surgical treatment options for patients with HD. A comprehensive search of the PubMed and the Web of Science databases was conducted from their inception to September 15th, 2022. Search terms included \"juvenile muscular atrophy of upper extremity\", \"Hirayama disease\" and \"surgery\". A total of 169 relevant publications were identified and 29 articles were finally reviewed. Current surgical treatments for HD are either anterior cervical surgery or posterior cervical surgery. The two approaches can effectively stop the disease. However, no studies have compared the advantages and limitations of the two surgical methods. The previous view that HD can be improved with conservative treatment has been challenged. In many studies, surgical treatment has been shown to improve the hand function in patients with HD. However, there is still controversy about the methods of anterior and posterior cervical surgery. Future research could focus on exploring the advantages and limitations of different surgeries.</p>","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709617/pdf/irdr-11-173.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40458325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insights from a patient with chronic lymphocytic leukemia complicating ALK+ anaplastic large cell lymphoma. 慢性淋巴细胞白血病合并ALK+间变性大细胞淋巴瘤1例分析
IF 1.3 Q2 Medicine Pub Date : 2022-11-01 DOI: 10.5582/irdr.2022.01086
Wuqiang Lin, Xiuli Chen, Zhenjie Cai, Heyong Zheng, Hanxing Huang, Huanxing Yang, Jianda Hu, Jing Zheng, Tetsuya Asakawa

Chronic lymphocytic leukemia (CLL) that transforms into a more aggressive lymphoma has been termed Richter syndrome (RS). CLL with T-cell neoplasia is rarely reported; those with ALK+ anaplastic large cell lymphoma (ALCL) are also exceedingly rarely reported. A 63-year-old woman from the south of China presented with generalized lymphadenectasis and fever; she already had a prior diagnosis of CLL 9 years ago. As per her current diagnosis, it was CLL with ALK+ ALCL. The two-lymph node and bone marrow biopsies presented two types of cellular groups: i) left cervical lymph node biopsy suggested CLL (Ki67: 10%), along with bone marrow biopsy exhibited enhancement of the small lymphocytes (30%) with scant cytoplasm, round or irregular cell nuclei, and massive amounts of chromatin. Large cells (< 1%) that expressed CD30 and ALK were visible; The results of immunohistochemistry were as follows: CD20 (weak positive); PAX5 (positive); CD23 and CD5 (weak positive); and CD3, CD10, and CyclinD1 (negative); ii) left supraclavicular lymph node biopsy suggested ALK+ ALCL (Ki67: 70%). The final diagnosis was CLL with ALCL. The mechanisms of this condition are not fully understood, which might be associated with chronic stimulation of T cells by CLL cells along with immune dysfunction.

慢性淋巴细胞白血病(CLL)转化为更具侵袭性的淋巴瘤被称为Richter综合征(RS)。CLL合并t细胞瘤很少报道;ALK+间变性大细胞淋巴瘤(ALCL)也极少报道。中国南方一名63岁妇女,表现为全身淋巴结肿大和发热;她早在9年前就被诊断出患有慢性淋巴细胞白血病。根据她目前的诊断,是CLL + ALK+ ALCL。双淋巴结和骨髓活检显示两种类型的细胞群:i)左侧颈部淋巴结活检提示CLL (Ki67: 10%),骨髓活检显示小淋巴细胞增强(30%),胞质较少,细胞核圆形或不规则,大量染色质。可见表达CD30和ALK的大细胞(< 1%);免疫组化结果如下:CD20(弱阳性);PAX5(正面);CD23和CD5(弱阳性);CD3、CD10和CyclinD1(阴性);ii)左侧锁骨上淋巴结活检提示ALK+ ALCL (Ki67: 70%)。最终诊断为CLL合并ALCL。这种情况的机制尚不完全清楚,可能与CLL细胞对T细胞的慢性刺激以及免疫功能障碍有关。
{"title":"Insights from a patient with chronic lymphocytic leukemia complicating ALK<sup>+</sup> anaplastic large cell lymphoma.","authors":"Wuqiang Lin,&nbsp;Xiuli Chen,&nbsp;Zhenjie Cai,&nbsp;Heyong Zheng,&nbsp;Hanxing Huang,&nbsp;Huanxing Yang,&nbsp;Jianda Hu,&nbsp;Jing Zheng,&nbsp;Tetsuya Asakawa","doi":"10.5582/irdr.2022.01086","DOIUrl":"https://doi.org/10.5582/irdr.2022.01086","url":null,"abstract":"<p><p>Chronic lymphocytic leukemia (CLL) that transforms into a more aggressive lymphoma has been termed Richter syndrome (RS). CLL with T-cell neoplasia is rarely reported; those with ALK<sup>+</sup> anaplastic large cell lymphoma (ALCL) are also exceedingly rarely reported. A 63-year-old woman from the south of China presented with generalized lymphadenectasis and fever; she already had a prior diagnosis of CLL 9 years ago. As per her current diagnosis, it was CLL with ALK<sup>+</sup> ALCL. The two-lymph node and bone marrow biopsies presented two types of cellular groups: <i>i</i>) left cervical lymph node biopsy suggested CLL (Ki67: 10%), along with bone marrow biopsy exhibited enhancement of the small lymphocytes (30%) with scant cytoplasm, round or irregular cell nuclei, and massive amounts of chromatin. Large cells (< 1%) that expressed CD30 and ALK were visible; The results of immunohistochemistry were as follows: CD20 (weak positive); PAX5 (positive); CD23 and CD5 (weak positive); and CD3, CD10, and CyclinD1 (negative); <i>ii</i>) left supraclavicular lymph node biopsy suggested ALK<sup>+</sup> ALCL (Ki67: 70%). The final diagnosis was CLL with ALCL. The mechanisms of this condition are not fully understood, which might be associated with chronic stimulation of T cells by CLL cells along with immune dysfunction.</p>","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709618/pdf/irdr-11-196.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40457889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge level of medical students and physicians about rare diseases in Lima, Peru. 秘鲁利马地区医学生和医生罕见病知识水平调查
IF 1.3 Q2 Medicine Pub Date : 2022-11-01 DOI: 10.5582/irdr.2022.01079
Andrea Flores, Sarah Burgos, Hugo Abarca-Barriga

Rare diseases (RDs) affect up to 8% of the world's population, and unfortunately, health professionals have a low level of knowledge regarding the impacts of RDs on the social, psychological, and economic spheres of the patients and their families; hence, RD management is inadequate, consistently empirical, and precarious. The objective of this study was to determine the knowledge level of the medical students from a non-state university and physicians from Lima, Peru of RDs through a virtual survey for an analytical cross-sectional study. A total of 338 medical students and 382 physicians were surveyed. Results showed that several of the respondents (68.1% of students and 48.7% of physicians) had heard of the term "rare disease", but only a few stated that they had received any kind of training specific to it. Of the physicians, 46.6% considered that there should be a course about RDs in medical curricula, and more than 60% considered RDs a public health problem. Most respondents prioritized the planning of a higher budget for common diseases and believe it is convenient to allocate a specific fund for RDs. More than half of the participants had a very poor knowledge level. Due to students and physicians' low level of general knowledge of RDs, it is important to raise awareness and improve their education about these pathologies because this will have beneficial effects for RD patient care.

罕见病(RDs)影响到世界人口的8%,不幸的是,卫生专业人员对RDs对患者及其家庭的社会、心理和经济领域的影响知之甚少;因此,研发管理是不充分的,始终是经验主义的,不稳定的。本研究的目的是通过一项分析性横断面研究的虚拟调查,确定来自一所非州立大学的医学生和来自秘鲁利马的医生对rd的知识水平。共有338名医学生和382名医生接受了调查。结果显示,一些答复者(68.1%的学生和48.7%的医生)听说过“罕见病”一词,但只有少数人表示他们接受过任何针对罕见病的培训。46.6%的医生认为应在医学课程中开设关于rd的课程,60%以上的医生认为rd是一个公共卫生问题。大多数答复者优先考虑为常见病规划更高的预算,并认为为研发分配专项资金是方便的。超过一半的参与者的知识水平很差。由于学生和医生对RD的一般知识水平较低,提高他们对这些病理的认识和教育是很重要的,因为这将对RD患者的护理产生有益的影响。
{"title":"Knowledge level of medical students and physicians about rare diseases in Lima, Peru.","authors":"Andrea Flores,&nbsp;Sarah Burgos,&nbsp;Hugo Abarca-Barriga","doi":"10.5582/irdr.2022.01079","DOIUrl":"https://doi.org/10.5582/irdr.2022.01079","url":null,"abstract":"<p><p>Rare diseases (RDs) affect up to 8% of the world's population, and unfortunately, health professionals have a low level of knowledge regarding the impacts of RDs on the social, psychological, and economic spheres of the patients and their families; hence, RD management is inadequate, consistently empirical, and precarious. The objective of this study was to determine the knowledge level of the medical students from a non-state university and physicians from Lima, Peru of RDs through a virtual survey for an analytical cross-sectional study. A total of 338 medical students and 382 physicians were surveyed. Results showed that several of the respondents (68.1% of students and 48.7% of physicians) had heard of the term \"rare disease\", but only a few stated that they had received any kind of training specific to it. Of the physicians, 46.6% considered that there should be a course about RDs in medical curricula, and more than 60% considered RDs a public health problem. Most respondents prioritized the planning of a higher budget for common diseases and believe it is convenient to allocate a specific fund for RDs. More than half of the participants had a very poor knowledge level. Due to students and physicians' low level of general knowledge of RDs, it is important to raise awareness and improve their education about these pathologies because this will have beneficial effects for RD patient care.</p>","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709623/pdf/irdr-11-180.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40546597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Interstitial deletions in the proximal regions of 6q: 12 original cases and a literature review. 6q近端间质缺失:12例原始病例和文献回顾。
IF 1.3 Q2 Medicine Pub Date : 2022-08-01 DOI: 10.5582/irdr.2022.01065
Osamu Machida, Keiko Yamamoto Shimojima, Takashi Shiihara, Satoshi Akamine, Ryutaro Kira, Yuiko Hasegawa, Eriko Nishi, Nobuhiko Okamoto, Satoru Nagata, Toshiyuki Yamamoto

Interstitial microdeletions in the proximal region of the long arm of chromosome 6 are rare. Herein we have reported 12 patients with developmental delays associated with interstitial microdeletions in 6q ranging from q12 to q22. The microdeletions were detected by chromosomal microarray testing. To confirm the clinical significance of these deletions, genotype-phenotype correlation analysis was performed using genetic and predicted loss-of-function data. SIM1 was recognized as the gene responsible for developmental delay, particularly in Prader-Willi syndrome-like phenotypes. Other genes possibly related to developmental delay were ZNF292, PHIP, KCNQ5, and NUS1. To further establish the correlation between the genotype and phenotype, more patient information is required.

6号染色体长臂近端间质微缺失是罕见的。在此,我们报告了12例与6q间质微缺失相关的发育迟缓患者,范围从q12到q22。通过染色体微阵列检测检测微缺失。为了确认这些缺失的临床意义,使用遗传和预测功能丧失数据进行基因型-表型相关分析。SIM1被认为是导致发育迟缓的基因,特别是在Prader-Willi综合征样表型中。其他可能与发育迟缓相关的基因有ZNF292、PHIP、KCNQ5和NUS1。为了进一步确定基因型和表型之间的相关性,需要更多的患者信息。
{"title":"Interstitial deletions in the proximal regions of 6q: 12 original cases and a literature review.","authors":"Osamu Machida,&nbsp;Keiko Yamamoto Shimojima,&nbsp;Takashi Shiihara,&nbsp;Satoshi Akamine,&nbsp;Ryutaro Kira,&nbsp;Yuiko Hasegawa,&nbsp;Eriko Nishi,&nbsp;Nobuhiko Okamoto,&nbsp;Satoru Nagata,&nbsp;Toshiyuki Yamamoto","doi":"10.5582/irdr.2022.01065","DOIUrl":"https://doi.org/10.5582/irdr.2022.01065","url":null,"abstract":"<p><p>Interstitial microdeletions in the proximal region of the long arm of chromosome 6 are rare. Herein we have reported 12 patients with developmental delays associated with interstitial microdeletions in 6q ranging from q12 to q22. The microdeletions were detected by chromosomal microarray testing. To confirm the clinical significance of these deletions, genotype-phenotype correlation analysis was performed using genetic and predicted loss-of-function data. <i>SIM1</i> was recognized as the gene responsible for developmental delay, particularly in Prader-Willi syndrome-like phenotypes. Other genes possibly related to developmental delay were <i>ZNF292</i>, <i>PHIP</i>, <i>KCNQ5</i>, and <i>NUS1</i>. To further establish the correlation between the genotype and phenotype, more patient information is required.</p>","PeriodicalId":14420,"journal":{"name":"Intractable & rare diseases research","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438003/pdf/irdr-11-143.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33507039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Intractable & rare diseases research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1